Skip to main content

Hepion Pharmaceuticals, Inc. (HEPA)

NASDAQ: HEPA · Delayed Price · USD
1.56
+0.01 (0.65%)
Pre-market:Sep 23, 2021 4:05 AM EDT
1.55
0.05 (3.33%)
At close: Sep 22, 4:00 PM
Market Cap118.15M
Revenue (ttm)n/a
Net Income (ttm)-24.92M
Shares Out76.23M
EPS (ttm)-0.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume622,051
Open1.52
Previous Close1.50
Day's Range1.50 - 1.57
52-Week Range1.36 - 3.69
Beta1.18
AnalystsBuy
Price Target6.33 (+308.4%)
Est. Earnings DateNov 15, 2021

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered...

IndustryPharmaceuticals
CEORobert Foster
Employees13
Stock ExchangeNASDAQ
Ticker SymbolHEPA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is 6.33, which is an increase of 308.39% from the latest price.

Price Target
$6.33
(308.39% upside)
Analyst Consensus: Buy

News

Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial. Related Content:   Hepion Pharma's NASH Candidate Aces Mid-Stage Study.

1 week ago - Benzinga

Why Are Hepion Pharma Shares Moving Higher Premarket Monday?

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today, Hepion will share additional data f...

1 week ago - Benzinga

Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in ...

EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

1 week ago - GlobeNewsWire

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols:LPTXNYMXVSTM
2 weeks ago - PennyStocks

Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders

EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...

1 month ago - GlobeNewsWire

Hepion Pharma's NASH Candidate Aces Mid-Stage Study

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive topline results from its Phase 2a AMBITION NASH clinical trial evaluating CRV431, a potent inhibitor of cyclophilins. In the trial, CRV43...

2 months ago - Benzinga

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting

EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...

2 months ago - GlobeNewsWire

Hepion Pharmaceuticals to be Added to the Russell Microcap® Index

EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeu...

3 months ago - GlobeNewsWire

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Tr...

EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of...

4 months ago - GlobeNewsWire

Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress

EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven thera...

4 months ago - GlobeNewsWire

7 Penny Stocks That May Have Room to Run Higher

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other symbols:AGRXAQMSCKPTIFRXLLNW
5 months ago - InvestorPlace

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharma...

EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven thera...

5 months ago - GlobeNewsWire

ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials

Hepion to include ENDRA's TAEUS Ⓡ technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic...

Other symbols:NDRA
6 months ago - Accesswire

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic d...

6 months ago - Accesswire

Hepion Pharmaceuticals Announces Pricing of Public Offering

EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...

7 months ago - GlobeNewsWire

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences

EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic ...

8 months ago - Accesswire

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for...

CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / ACC...

8 months ago - Accesswire

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBIT...

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort...

8 months ago - Accesswire

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19

- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID-1...

9 months ago - Accesswire

Hepion Pharmaceuticals (HEPA) Jumps: Stock Rises 9%

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock?

Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

1 year ago - Seeking Alpha

Why Hepion Pharmaceuticals Is Trading Higher Today

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading higher after the company reported its CRV431 demonstrated efficacy in Kidney Fibrosis.

1 year ago - Benzinga

Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Other symbols:AHPIGILDGNMKNVSREGN
1 year ago - Seeking Alpha

'5 Stocks' in Focus as Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other symbols:HSIIJBGSNWBITHG
1 year ago - Zacks Investment Research